openFDA
Cure8 regulatory brief
Prednisone delayed release FDA label update (2026-09-23)
Medications
Prednisone
Corticosteroids
Steroids
Osteoporosis
Anemia
Regulatory Update
Adult patients
Why This Matters
This FDA label update lists prednisone delayed‑release tablets as an option for short‑term treatment of Crohn’s disease and ulcerative colitis and reiterates important safety monitoring and pregnancy-related risks. Patients on prednisone may need extra monitoring and precautions.
Who Should Pay Attention
Adults and pediatric patients with IBD who are prescribed prednisone, clinicians managing IBD or prescribing corticosteroids, and pregnant patients or those planning pregnancy.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This label update summarizes approved indications and safety information for prednisone delayed-release tablets.
It names Crohn’s disease and ulcerative colitis among gastrointestinal indications and highlights common steroid-related risks: adrenal (HPA) suppression, higher infection risk, elevated blood pressure and electrolytes changes, GI perforation risk in certain GI disorders, mood/behavior changes, decreased bone density, and potential fetal harm.
If you take prednisone chronically, the label emphasizes the need for monitoring (blood pressure, electrolytes, bone density, signs of infection), gradual tapering to avoid adrenal insufficiency, and avoiding live vaccines while on immunosuppressive doses. It also notes special pediatric and pregnancy considerations.
This entry reflects the drug label content and does not provide medical advice. Talk with your clinician about how this label information applies to your treatment and monitoring plan.
Keep In Mind
This is a regulatory drug‑label record (DailyMed) summarizing official indications and safety information. It does not present new clinical trial results. For personal treatment decisions, consult your healthcare provider.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorDr. Reddys Laboratories Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedSep 23, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A cross-sectional study on pharmacotherapy and predictors of clinical remission in patients with inflammatory bowel disease.
Medication choices and adherence are central to IBD management. This study highlights that adherence was strongly associated with being in clinical remission, and that commonly used drugs included mesalamine and...
Pharmacological management of Crohn's disease of the pouch - a phenotype-based review.
Crohn's-like disease of the pouch is a meaningful complication after IPAA that can impair quality of life and risk pouch failure; knowing which drug classes show promise for specific pouch phenotypes can guide...
Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations☆ Aspectos y consideraciones generales en la enfermedad inflamatoria intestinal durante la pandemia por COVID-19
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...